Literature DB >> 28541025

Structural genomic variations and Parkinson's disease.

Sara Bandrés-Ciga1, Clara Ruz1, Francisco J Barrero2, Francisco Escamilla-Sevilla2, Javier Pelegrina2, Francisco Vives1, Raquel Duran3.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease, whose prevalence is projected to be between 8.7 and 9.3 million by 2030. Until about 20 years ago, PD was considered to be the textbook example of a "non-genetic" disorder. Nowadays, PD is generally considered a multifactorial disorder that arises from the combination and complex interaction of genes and environmental factors. To date, a total of 7 genes including SNCA, LRRK2, PARK2, DJ-1, PINK 1, VPS35 and ATP13A2 have been seen to cause unequivocally Mendelian PD. Also, variants with incomplete penetrance in the genes LRRK2 and GBA are considered to be strong risk factors for PD worldwide. Although genetic studies have provided valuable insights into the pathogenic mechanisms underlying PD, the role of structural variation in PD has been understudied in comparison with other genomic variations. Structural genomic variations might substantially account for such genetic substrates yet to be discovered. The present review aims to provide an overview of the structural genomic variants implicated in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28541025     DOI: 10.23736/S0026-4806.17.05246-6

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  7 in total

Review 1.  Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease.

Authors:  Amy R Dunn; Kristen M S O'Connell; Catherine C Kaczorowski
Journal:  Neurosci Biobehav Rev       Date:  2019-06-14       Impact factor: 8.989

2.  Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease.

Authors:  Yanyun Sun; Xiao-Jun Lu; Xinghui Fu; Ye Zhang; Yan Zhan; Jiabing Liu; Lingxia Zhao; Chun-Lin Xia
Journal:  Mol Cell Biochem       Date:  2020-10-17       Impact factor: 3.396

3.  Association between the DRD2 TaqIA gene polymorphism and Parkinson disease risk: an updated meta-analysis.

Authors:  Ming Yu; Feiran Huang; Wei Wang; Chen Zhao
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 4.  Genetically Targeted Clinical Trials in Parkinson's Disease: Learning from the Successes Made in Oncology.

Authors:  Magnus Sjögren; Henri J Huttunen; Per Svenningsson; Håkan Widner
Journal:  Genes (Basel)       Date:  2021-09-28       Impact factor: 4.096

5.  DRD2 Taq1A Polymorphism-Related Brain Volume Changes in Parkinson's Disease: Voxel-Based Morphometry.

Authors:  Kenji Ohira; Hajime Yokota; Shigeki Hirano; Motoi Nishimura; Hiroki Mukai; Takuro Horikoshi; Setsu Sawai; Yoshitaka Yamanaka; Tatsuya Yamamoto; Shingo Kakeda; Satoshi Kuwabara; Tomoaki Tanaka; Takashi Uno
Journal:  Parkinsons Dis       Date:  2022-03-28

Review 6.  Drosophila melanogaster Mitochondrial Carriers: Similarities and Differences with the Human Carriers.

Authors:  Rosita Curcio; Paola Lunetti; Vincenzo Zara; Alessandra Ferramosca; Federica Marra; Giuseppe Fiermonte; Anna Rita Cappello; Francesco De Leonardis; Loredana Capobianco; Vincenza Dolce
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

Review 7.  Genetic Risk Profiling in Parkinson's Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways.

Authors:  Ashley Hall; Sara Bandres-Ciga; Monica Diez-Fairen; John P Quinn; Kimberley J Billingsley
Journal:  Int J Mol Sci       Date:  2020-10-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.